[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":334},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,47,78,106,134,171,195,221,258,283,308],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100637713","effect-of-oral-calcium-butyrate-supplementation-in-obesity-100637713",false,"NCT07583017","Effect of Oral Calcium Butyrate Supplementation in Obesity","Effect of Oral Calcium Butyrate Supplementation on Monocyte Mitochondrial Function and Gut Microbiota in Adults With Obesity","Pacayeliztli","Inclusion Criteria:\n\n* Signing of the informed consent form.\n* Adults aged ≥18 years of age.\n* Body mass index (BMI) \\>30 kg\u002Fm².\n* Both sex\n\nExclusion Criteria:\n\n* Diabetes mellitus, defined as fasting glucose \\>126 mg\u002FdL during screening.\n* Hypertension, defined as blood pressure ≥130\u002F80 mmHg during screening.\n* Chronic kidney disease or estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m².\n* Known liver disease.\n* Secondary causes of obesity or diabetes, including Cushing syndrome, clinical or subclinical hypothyroidism, or pheochromocytoma.\n* Catabolic diseases such as cancer or acquired immunodeficiency syndrome.\n\nDrug treatment:\n\n* Antihypertensive drugs or treatment (thiacycline, loop or potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, alpha blockers, calcium antagonists, beta blockers).\n* Treatment with hypoglycemic agents (sulfonylureas, biguanides, incretins) or insulin and antidiabetic drugs.\n* Treatment with statins, fibrates or other drugs to control dyslipidemia.\n* Use of antibiotics in the three months prior to the study.\n* Use of steroid drugs, chemotherapy, immunosuppressants, or radiation therapy.\n* Anorexigenic or that accelerate weight loss such as sibutramine or orlistat.\n* Supplements with any of the functional foods used in the study.\n* Probiotic, prebiotic or symbiotic supplements.\n* Chronic proton pump inhibitor use or use within the last 2 weeks.\n* Chronic use of laxatives, antispasmodics, or medications affecting intestinal motility.\n* Current tobacco use.\n* Daily alcohol consumption \\>1 drink\u002Fday during the last month.\n* Use of recreational psychoactive substances.\n* Pregnancy or lactation.\n* Bariatric surgery or participation in intensive weight loss programs.\n* Weight loss ≥3 kg in less than 3 months.","ALL","18 Years",{"count":20,"type":21},42,"ESTIMATED","INTERVENTIONAL",[24],"NA","Obesity is characterized by gut microbiota dysbiosis, in which beneficial metabolites such as butyrate are reduced. Butyrate is a short-chain fatty acid produced by microbial fermentation that plays a key role in maintaining intestinal barrier integrity, regulating immune responses, and supporting mitochondrial function. Its depletion contributes to disruption of the intestinal barrier, facilitating the translocation of bacterial components and promoting systemic inflammation mediated by immune cell activation, like monocytes. This chronic inflammatory state is associated with mitochondrial dysfunction and impaired cellular bioenergetics. Butyrate has been investigated for its anti-inflammatory and metabolic effects, however, its direct impact on monocyte mitochondrial function and its relationship with gut microbiota composition in humans remains unclear.\n\nThis randomized, double-blind, placebo-controlled trial will evaluate the effect of oral calcium butyrate supplementation (1000 mg\u002Fday) compared with placebo for 4 weeks in adults with obesity. The primary objective is to determine the change in monocyte mitochondrial maximal respiration baseline to week 4.",[27],"Obesity",[27,29,30,31,32,33],"Butyrate","Gut microbiota","mitochondria","monocyte","short chain fatty acid","NOT_YET_RECRUITING","2026-05-07",{"date":37,"type":38},"2026-05-13","ACTUAL",{"date":40,"type":21},"2026-08-01",{"date":42,"type":21},"2028-12-30",{"name":44,"class":45},"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":46},"100593310","effect-of-consuming-n-3-polyunsaturated-fatty-acids-rich-foods-on-triglyceride-concentration-and-lipoprotein-composition-100593310","NCT07004777","Effect of Consuming n-3 Polyunsaturated Fatty Acids Rich Foods on Triglyceride Concentration and Lipoprotein Composition","Effect of Consuming n-3 Polyunsaturated Fatty Acids Rich Foods on Triglyceride Concentration and Lipoprotein Composition in Individuals With Hypertriglyceridemia. Controlled Clinical Trial.","SALVIMEX","Inclusion Criteria:\n\n* Signing of the informed consent form\n* Both sexes.\n* Adults over 18 years of age.\n* BMI \\>18.5 kg\u002Fm2.\n* Triglycerides between 200 and 500 mg\u002FdL.\n* Total cholesterol less than 240 mg\u002FdL\n\nExclusion Criteria:\n\n* Any type of diabetes.\n* kidney disease diagnosed by a physician.\n* Acquired diseases that secondarily cause obesity and diabetes.\n* Patients who have suffered a cardiovascular event.\n* Weight loss \\>3 kg in the last 3 months.\n* Catabolic diseases such as cancer and acquired immunodeficiency syndrome.\n* Pregnancy.\n* Treatment with any medication:\n* Treatment with antihypertensive drugs (tricyclic, loop, or potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, alpha-blockers, calcium channel blockers, beta-blockers).\n* Treatment with hypoglycemic agents (sulfonylureas, biguanides, incretins) or - insulin and antidiabetics.\n* Treatment with statins, fibrates, or other drugs to control dyslipidemia.\n* Use of steroid medications, chemotherapy, immunosuppressants, or radiation therapy.\n* Anorectic agents or those that accelerate weight loss.\n* Treatment with any medication that influences inflammation (corticosteroids, nonsteroidal anti-inflammatory drugs, colchicine, interleukin-1 inhibitors) or triglyceride metabolism (metformin, glitazones, SGLT2 inhibitors, fibrates, statins, cholesterol ester transporter protein (CETP) inhibitors, pancreatic lipase inhibitors).\n* Anticoagulants and antiplatelets (warfarin, aspirin, clopidogrel).\n* People with a smoking cessation index (SCI) greater than 21.\n* People with a tobacco Index greater than 21.\n* Consumption of large amounts of alcohol (14 drinks for women or 21 drinks for men in a typical week).\n* Consumption of any recreational psychoactive substance.\n* Allergy or intolerance to any food listed in the proposed pantry.\n* Unwillingness to consume any of the foods listed in the proposed pantry.\n* Previous n-3 PUFA supplementation.",true,{"count":57,"type":21},375,[24],"Hypertriglyceridemia is one of the most prevalent lipid profile disorders and is linked to a large proportion of mortality in Mexico and around the world. Various international treatment guidelines for hypertriglyceridemia have suggested the consumption of foods rich in n-3 polyunsaturated fatty acids or their intake through supplementation as a complement to lifestyle changes. However, adherence to the consumption of foods and supplements containing these fatty acids is often limited due to lack of acceptance or unaffordability. For this reason the objective of the study is to evaluate the effect of including Mexican foods rich in n-3 polyunsaturated fatty acids (chia seeds and pumpkin seeds) within a diet based on NCEP-ATPIII recommendations on triacylglycerol concentration and fatty acid profile in people with hypertriglyceridemia.\n\nThe study will consist of a 4-week period in which one group of participants will be randomized into two treatment groups: 1)isocaloric diet based on the NCEP-ATPIII dietary recommendations; 2) isocaloric diet based on the NCEP-ATPIII dietary recommendations plus chia and pumpkin seeds. The effect of the dietary intervention will be assessed by concentration of triglycerides, fatty acids profile and lipoprotein analysis.",[61],"Hypertriglyceridemia",[61,63,64,65,66,67,68],"Lipid metabolism","Dyslipidemia","Fatty Acids, Omega-3","Eicosapentaenoic Acid","Docosahexaenoic Acid","diet","RECRUITING","2026-04-09",{"date":72,"type":38},"2026-04-14",{"date":74,"type":38},"2026-02-01",{"date":76,"type":21},"2027-06-30",{"name":44,"class":45},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":46},"100545329","phase-4-melatonins-effect-on-nighttime-blood-pressure-and-sleep-in-osa-patients-mebp-osa-100545329","NCT06380491","Melatonin's Effect on Nighttime Blood Pressure and Sleep in OSA Patients (MEBP-OSA)","Impact of Melatonin Treatment on Blood Pressure Circadian Rhythm, Sleep and Metabolic Variables.","MEBP-OSA","Inclusion Criteria:\n\n* Polisomnographic diagnosis of Obstructive Sleep Apnea\n* Non-dipping blood pressure on Ambulatory blood pressure monitoring (ABPM):\n\nExclusion Criteria:\n\n* Use of sleep or psychiatric medication\n* Use of Positive Airway Pressure (CPAP or Bipap)\n* Neurologic or psychiatric disorder","60 Years",{"count":88,"type":21},50,[90],"PHASE4","The goal of this clinical trial is to learn if melatonin works to treat comorbid insomnia in adults with OSA and nocturnal non-dipping blood pressure pattern.\n\nThe main question it aims to answer is:\n\nDoes melatonin maintain sleep during night and recover the dipping blood pressure pattern?",[93],"Obstructive Sleep Apnea of Adult",[95,96,97],"Circadian Blood Pressure Rhythm","Obstructive sleep apnea","Melatonin","2026-03-30",{"date":100,"type":38},"2026-04-01",{"date":102,"type":38},"2023-06-22",{"date":104,"type":21},"2028-01-22",{"name":44,"class":45},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":120,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":46},"100589344","intraoperative-hypotension-in-pancreatoduodenectomy-a-randomized-trial-of-general-versus-combined-anesthesia-100589344","NCT06953193","Intraoperative Hypotension in Pancreatoduodenectomy: A Randomized Trial of General Versus Combined Anesthesia","Inclusion Criteria:\n\n* Signed written informed consent.\n* Patients scheduled for elective pancreatoduodenectomy at National Institute of Medical Sciences and Nutrition Salvador Zubirán.\n* No contraindications for neuroaxial anesthesia (epidural catheter placement), including:\n\n  * Generalized or localized infection at the puncture site.\n  * Thrombocytopenia.\n  * Coagulation disorders.\n  * Intracranial hypertension.\n  * Patient refusal.\n\nExclusion Criteria:\n\n* Age under 18 years.\n* Pregnancy.\n* Inability to randomize the case due to specific circumstances (such as contraindications to epidural use), resulting in non-eligibility based on participation criteria.",{"count":113,"type":21},206,[24],"This randomized clinical trial compares the hemodynamic effects of general anesthesia versus combined general anesthesia (thoracic epidural) in patients undergoing pancreatoduodenectomy. The primary aim is to assess the incidence of intraoperative hypotension and related adverse events. Secondary outcomes includes vasopressor requirements, transfusion needs, postoperative complications, intensive care unit admission, hospital length of stay, and mortality.",[117,118,119],"Pancreatic Neoplasms","Hypotension","Pancreatoduodenectomy",[121,122,123,124,125,126],"Pancreatic Surgery","General Anesthesia","Hemodynamic Changes","Vasopressors","Postoperative Complications","Combined Anesthesia","2026-03-27",{"date":100,"type":38},{"date":130,"type":38},"2025-04-07",{"date":132,"type":21},"2030-04-30",{"name":44,"class":45},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":153,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":46},"100619739","expanded-hemodialysis-versus-high-volume-online-hemodiafiltration-for-uremic-toxin-removal-100619739","NCT07348536","Expanded Hemodialysis Versus High-Volume Online Hemodiafiltration for Uremic Toxin Removal","Impact of Expanded Hemodialysis Prescription on Global Uremic Toxin Removal Compared With High-Volume Online Hemodiafiltration: A Randomized Open-Label Crossover Study","REMOV-HDx","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* End stage renal disease Receiving maintenance hemodialysis three times per week on expanded hemodialysis as part of routine care for at least 1 month\n* On dialysis treatment for more than 3 months\n* Minimal or no residual urine output (less than 100 mL per day)\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Vascular access unable to support a blood flow of at least 300 mL\u002Fmin",{"count":143,"type":21},15,[24],"People with advanced kidney disease need dialysis to remove waste products from the blood. Some of these waste products, called uremic toxins, are small, while others are medium-sized and more difficult to remove. Poor removal of these toxins may contribute to symptoms and long-term complications in patients on dialysis.\n\nTwo dialysis techniques are commonly used to improve toxin removal beyond standard hemodialysis: expanded hemodialysis (HDx) using medium cut-off membranes, and high-volume online hemodiafiltration (HV-OL-HDF). Although both techniques are effective, the best way to prescribe expanded hemodialysis-particularly the ideal treatment time-has not been clearly defined.\n\nThe purpose of this study is to compare how well different treatment times of expanded hemodialysis remove small and medium-sized uremic toxins, and to compare these results with high-volume online hemodiafiltration. Toxin removal will be evaluated using a combined measurement called the Global Removal Score, which summarizes the removal of several important waste substances.\n\nThis is a single-center, randomized, open-label, crossover study. Adults receiving maintenance hemodialysis will receive three different expanded hemodialysis sessions with different treatment durations (180, 210, and 240 minutes), followed by one session of high-volume online hemodiafiltration. Blood samples will be taken before and after each dialysis session to measure toxin levels.\n\nThe results of this study may help determine whether expanded hemodialysis with shorter or standard treatment times can achieve toxin removal similar to high-volume hemodiafiltration, which could support more personalized and practical dialysis prescriptions.",[147,148,149,150,151,152],"End Stage Renal Disease (ESRD)","Chronic Kidney Disease on Hemodialysis","Renal Dialysis","Uremia; Chronic","Hemodialysis","Hemodiafiltration",[154,155,156,157,158,159,160,161,162],"Expanded hemodialysis","High-volume online hemodiafiltration","Medium cut-off dialysis membranes","Uremic toxin removal","Middle molecule clearance","Chronic kidney failure","Dialysis dose optimization","Dialysis treatment time","Global removal score","2026-03-23",{"date":165,"type":38},"2026-03-24",{"date":167,"type":21},"2026-04",{"date":169,"type":21},"2029-12",{"name":44,"class":45},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":46},"100583983","pre-surgical-immunonutritions-effect-on-colorectal-surgery-100583983","NCT06883422","Pre-Surgical Immunonutrition's Effect on Colorectal Surgery","Impact of Pre-surgical Oral Immunonutrition on Plasma Levels of Branched-chain Amino Acids in Elective Colorectal Surgery Patients: a Randomized, Double-blind, Controlled, Clinical Trial","Inclusion Criteria:\n\n* Both sexes\n* Over 18 years of age\n* Scheduled for elective colorectal surgery (Resection and intestinal reconnection)\n* Obtaining patient consent\n\nExclusion Criteria:\n\n* Consumption of nutritional supplements during the 2 weeks prior to patient enrollment\n* Consumption of additional nutritional supplements during the 7 days corresponding to the study intervention period\n* Patients diagnosed with chronic kidney disease\n* Patients diagnosed with hepatic cirrhosis\n* Documented allergy to any of the ingredients in the formulas under evaluation (milk and\u002For soy).",{"count":179,"type":21},126,[24],"Colorectal surgery patients face excessive catabolism, increasing inflammation and immune compromise. The administration of nutritional supplements known as immunonutrition before gastrointestinal surgery has been shown to improve clinical outcomes; however, the mechanisms underlying these benefits remain inconclusive.\n\nThe objective of the study is to evaluate the effect of preoperative nutritional supplementation with an immunonutrient-enriched formula compared to an isocaloric and isoproteic formula on plasma BCAA concentration in patients undergoing elective colorectal surgery. A double-blind, randomized controlled clinical trial will be conducted. Patients will be required to drink the supplement daily for the 7 days preceding the surgical intervention. Patients in both groups will be instructed to maintain their usual food intake. During the study, there will be two patient assessments and a review of medical records to document the outcomes.",[183],"Colorectal Surgery",[183,185,186,187,188],"Immunonutrition","Enhanced Recovery After Surgery","Preoperative Care","Amino Acids Branched-Chain",{"date":127,"type":38},{"date":191,"type":38},"2023-05-25",{"date":193,"type":21},"2026-12-31",{"name":44,"class":45},{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":203,"targetDuration":205,"studyType":206,"phases":4,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":218,"leadSponsor":220,"locationsCount":4},"100629448","outcomes-of-renal-replacement-in-mexico-100629448","NCT07474805","Outcomes of Renal Replacement in Mexico","Clinical Outcomes Study of Mexican Patients With Chronic Kidney Disease on Renal Replacement Therapy","ORReMex","Inclusion Criteria:\n\n* Willingness to participate and provision of written informed consent\n* Diagnosis of chronic kidney disease and treatment with hemodialysis or peritoneal dialysis for ≥3 months\n* Availability of a medical record containing information on the study variables\n* Receiving care at one of the participating centers\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C3 months due to a cause unrelated to chronic kidney disease",{"count":204,"type":21},290,"3 Years","OBSERVATIONAL","A descriptive, observational, prospective, multicenter study aimed at describing the main clinical outcomes of patients with chronic kidney disease receiving any form of renal replacement therapy in Mexico.",[209,148],"Chronic Kidney Disease - Stage V",[211,212,213],"Chronic kidney disease","Renal replacement therapy","Clinical outcomes","2026-03-12",{"date":216,"type":38},"2026-03-16",{"date":167,"type":21},{"date":219,"type":21},"2029-04",{"name":44,"class":45},{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":233,"conditions":234,"keywords":237,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":46},"100594375","phase-2-protecting-the-kidneys-proximal-tubules-from-platinum-based-chemotherapy-toxicity-100594375","NCT07018622","Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity","Effect of Sodium-Glucose Cotransporter 2 Inhibition on Urinary Biomarkers of Kidney Injury After Platinum-Based Chemotherapy","DAPA-ARMOR","Inclusion Criteria:\n\n* Signed informed consent form\n* Diagnosis of a solid tumor requiring a platinum-based chemotherapy regimen (cisplatin or carboplatin)\n* Expected survival \\> 4 months\n* ECOG performance status 0-2\n\nExclusion Criteria:\n\n* History of nephrectomy\n* History of kidney transplant\n* Concurrent use of known nephrotoxic drugs (e.g., aminoglycosides, amphotericin B, cyclophosphamide, ifosfamide, methotrexate)\n* Type 1 diabetes mellitus\n* Poorly controlled type 2 diabetes (HbA1c \\> 8% or fasting glucose \\> 200 mg\u002FdL in the past month)\n* Active glomerulopathy\n* Prior use of SGLT2 inhibitors or current indication for their use\n* eGFR \\\u003C 20 ml\u002Fmin\u002F1.73 m²\n* Active urinary tract infection\n* Unresolved obstructive uropathy\n* Participation in another clinical trial\n* History of recurrent genitourinary infections",{"count":230,"type":21},46,[232],"PHASE2","Patients with cancer who receive platinum-based chemotherapy are at increased risk of kidney injury caused by these drugs. This form of toxicity can lead to treatment delays, dose reductions, or permanent discontinuation of chemotherapy, all of which can negatively impact cancer outcomes and increase patient morbidity. Despite the clinical significance, there are currently no effective strategies to prevent platinum-induced kidney damage. Existing preventive measures-such as hydration, mannitol use, and magnesium supplementation-are limited and not always effective.\n\nThis clinical trial investigates whether a type of medication known as a Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor, specifically dapagliflozin, can protect the kidneys from damage during platinum-based chemotherapy in patients with solid tumors. Researchers believe that blocking SGLT2 in the kidney may reduce toxicity in the proximal tubules-the area most affected by platinum drugs.\n\nThe primary goal of this study is to compare the levels of a specific urinary biomarker of kidney injury (called KIM-1) 72 hours after chemotherapy, between patients who receive dapagliflozin and those who receive a placebo. Lower levels of this biomarker may indicate that dapagliflozin is helping protect the kidneys.\n\nSecondary goals include comparing additional urinary biomarkers of kidney damage and function-such as EGF (epidermal growth factor), N-acetyl-β-D-glucosaminidase (uNAG), albumin (AlbU), and β2-microglobulin (uβ2-m)-at 72 hours and 7 days after chemotherapy. The study will also assess:\n\nThe percentage of patients who develop acute kidney injury, Changes in estimated glomerular filtration rate (a measure of kidney function), Electrolyte abnormalities (sodium, magnesium, phosphorus), And any adverse events associated with dapagliflozin use. As exploratory objectives, the trial will also evaluate cancer treatment response between groups (using RECIST 1.1 criteria) and the overall safety and tolerability of dapagliflozin compared to placebo.\n\nThis is a randomized, double-blind, placebo-controlled clinical trial, meaning that participants will be randomly assigned to receive either dapagliflozin or a placebo, and neither the patients nor the study team will know who receives which treatment until the study ends.\n\nThe central hypothesis is that dapagliflozin will reduce urinary biomarkers of kidney injury by at least 50% compared to placebo, offering a potential protective strategy against platinum-induced nephrotoxicity without interfering with cancer treatment.",[235,236],"Solid Tumors","Cisplatin Nephrotoxicity",[235,238,239,240,241,242,243,244,245,246,247,248,249],"Platinum-Based Chemotherapy","Cisplatin","Carboplatin","Nephrotoxicity","Kidney Tubules, Proximal","SGLT2 Inhibitors","Kidney Injury Molecule-1","Renal Protection","Chemotherapy-Induced Kidney Injury","Randomized Controlled Trial","Urinary Biomarkers","Dapagliflozin","2026-03-09",{"date":252,"type":38},"2026-03-11",{"date":254,"type":38},"2025-05-07",{"date":256,"type":21},"2026-10-30",{"name":44,"class":45},{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":265,"targetDuration":4,"studyType":22,"phases":267,"briefSummary":268,"conditions":269,"keywords":272,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":46},"100494879","postprandial-glucose-levels-gut-microbiota-and-supplementation-with-functional-foods-in-adults-100494879","NCT05723913","Postprandial Glucose Levels, Gut Microbiota and Supplementation With Functional Foods in Adults","PPGR","Inclusion Criteria:\n\n* Male and female\n* Adults between 18 and 60 years of age.\n* The signing of the informed consent.\n\nExclusion Criteria:\n\n* Patients with any type of diabetes.\n* Patients with high blood pressure.\n* Patients with acquired diseases secondarily producing obesity and diabetes.\n* Patients who have suffered a cardiovascular event.\n* Patients with gastrointestinal diseases.\n* Weight loss \\> 3 kg in the last 3 months.\n* Catabolic diseases such as cancer and acquired immunodeficiency syndrome.\n* Pregnancy status.\n* Drug treatment:\n\n  * Antihypertensive drugs or treatment (thiacycline, loop or potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, alpha blockers, calcium antagonists, beta blockers).\n  * Treatment with hypoglycemic agents (sulfonylureas, biguanides, incretins) or insulin and antidiabetic drugs.\n  * Treatment with statins, fibrates or other drugs to control dyslipidemia.\n  * Use of antibiotics in the three months prior to the study.\n  * Use of steroid drugs, chemotherapy, immunosuppressants, or radiation therapy.\n  * Anorexigenic or that accelerate weight loss such as sibutramine or orlistat.\n  * Supplements with any of the functional foods used in the study.\n  * Probiotic, prebiotic or symbiotic supplements.",{"count":266,"type":21},200,[24],"This is a clinical study with participants over 18 years of age that meet the selection criteria. This will be 42-day study divided into three phases of 14 days each: 14 days without intervention, 14 days with intervention with functional foods and 14 days without intervention again. With the objective of assess the changes in the postprandial glycemic responses through the gut microbiota and urine metabolites.",[270,271],"Healthy","Nutritional and Metabolic Diseases",[273,30,274],"Postprandial glucose responses","Functional foods","2025-06-13",{"date":277,"type":38},"2025-06-18",{"date":279,"type":38},"2023-06-07",{"date":281,"type":21},"2026-10-01",{"name":44,"class":45},{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":291,"targetDuration":293,"studyType":206,"phases":4,"briefSummary":294,"conditions":295,"keywords":298,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":46},"100490394","registry-of-pulmonary-arterial-hypertension-associated-with-connective-tissue-diseases-reconnective-100490394","NCT05665556","REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE)","REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE) at the National Institute of Medical Sciences and Nutrition Salvador Zubirán","RECONNECTIVE","Inclusion Criteria:\n\n* Incident and prevalent patients diagnosed with Group I associated with Connective Tissue Diseases (CTD)\n* Incident and prevalent patients diagnosed with Group IV Pulmonary Arterial Hypertension (PAH) associated with Connective Tissue Diseases (CTD) with evidence of a chronic thromboembolic pulmonary disease by ventilation\u002Fperfusion pulmonary gammagraph or computed tomography pulmonary angiogram with at least three months of total anticoagulation therapy.\n* Patient diagnosed with a connective tissue disease according to the classification criteria of the American College of Rheumatology.\n* Precapillary pulmonary hypertension confirmed by right heart catheterization (RHC): Mean pulmonary arterial pressure (mPAP) \\>20 mm Hg with a pulmonary arterial wedge pressure ≤ 15 mm Hg and Pulmonary vascular resistance (PVR) ≥ 2.0 Wood units\n\nExclusion Criteria:\n\n* Patients who meet the criteria for another group of pulmonary hypertension (Groups II, III or V).",{"count":292,"type":21},170,"5 Years","The RECONNECTIVE Registry is an observational single center study, focused on the subgroup of precapillary pulmonary hypertension related to connective tissue diseases. All patients will have hemodynamic confirmation by right heart catheterization and will be follow-up for at least 5 years from admission. All patients diagnosed with Group I Pulmonary Arterial Hypertension (PAH) associated with Connective Tissue Diseases (CTD) and Group IV Pulmonary Hypertension (PH) with CTD will be included. The purpose of the registry is to learn and understand the clinical outcomes and natural history of the pulmonary arterial hypertension in this subgroup of patients to improve the medical care and treatment.",[296,297],"Pulmonary Arterial Hypertension","Connective Tissue Diseases",[296,299],"Connective Tissue Disease","2023-06-27",{"date":302,"type":38},"2023-06-29",{"date":304,"type":38},"2022-12-15",{"date":306,"type":21},"2027-12",{"name":44,"class":45},{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":315,"enrollmentInfo":316,"targetDuration":4,"studyType":22,"phases":318,"briefSummary":319,"conditions":320,"keywords":322,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":46},"100273253","validation-of-an-integrated-attention-model-for-patients-with-type-2-diabetes-100273253","NCT02836808","Validation of an Integrated Attention Model for Patients With Type 2 Diabetes","CAIPADI","Inclusion Criteria:\n\n* being over 18 and under 70 years old\n* having diagnosis of type 2 diabetes in the five previous years,\n* having family support\n* free of disabling diabetes complications\n\nExclusion Criteria:\n\n* advanced complications of diabetes, such as ischemic heart disease, heart failure NYHA III-IV, KDOQI ≥3 renal failure, amputations, cerebral vascular disease, gastroparesis and muscular atrophy .\n* type 1 diabetes mellitus, gestational diabetes or some variant of diabetes related to genetic syndromes, hyperlabile diabetes\n* co-morbidities that limit their life expectancy such as malignant tumors\n* advanced cognitive impairment or serious psychiatric disorders\n* smoking, alcoholism or illegal drug dependence\n* conditions that require surgical treatment in the short run or which prevent moderated activity.","70 Years",{"count":317,"type":21},1200,[24],"Abstract: Empowerment interventions for chronic diseases are an evolving process. No agreement exists regarding the necessary components and methodologies to be applied. Systematic reviews have assessed the effect of self-management interventions. Improvements in illness beliefs, adherence to drug therapy and glucose monitoring have been reported. In the long term, no major changes have been achieved in weight, physical activity, smoking status, and depression scores.\n\nThere is a need for additional studies. The Center for Comprehensive Care of Patients with Diabetes (CAIPaDi) program is an intervention designed to provide education and empowerment techniques (using simple low-cost interactive tools) over a short period of time followed by at-distance support using internet or cell phone technology. The target population consists of patients with type 2 diabetes, free of chronic complications who are non-smokers. The intervention is composed of four monthly visits followed by a continuous at-distance support system. At each visit, patients stay for six hours in the center. Information is presented in group sessions. Empowerment techniques are applied during individual exchanges with the team or during facilitated group sessions. In summary, empowerment programs are an unmet need in many healthcare services.",[321],"Type 2 Diabetes",[323,324,325],"Multidisciplinary interventions","Long term control","Empowerment","2018-03-02",{"date":328,"type":38},"2018-03-06",{"date":330,"type":38},"2013-10-31",{"date":332,"type":21},"2028-12-31",{"name":44,"class":45},""]